Neuphoria Therapeutics Inc.
NEUP
$4.40
$0.184.27%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -100.09% | 2,163.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.09% | 2,163.47% | |||
| Cost of Revenue | -425.12% | -6.97% | |||
| Gross Profit | -60.84% | 1,345.83% | |||
| SG&A Expenses | 47.19% | -46.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 92.30% | -25.42% | |||
| Operating Income | -148.75% | 452.40% | |||
| Income Before Tax | -181.84% | 678.82% | |||
| Income Tax Expenses | -228.33% | -800.00% | |||
| Earnings from Continuing Operations | -178.88% | 679.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -178.88% | 679.54% | |||
| EBIT | -148.75% | 452.40% | |||
| EBITDA | -146.72% | 475.63% | |||
| EPS Basic | -171.32% | 631.03% | |||
| Normalized Basic EPS | -175.93% | 630.40% | |||
| EPS Diluted | -171.33% | 630.92% | |||
| Normalized Diluted EPS | -175.93% | 630.40% | |||
| Average Basic Shares Outstanding | 10.60% | 9.14% | |||
| Average Diluted Shares Outstanding | 10.60% | 9.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||